Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Read Why $SOAC will be a great SPAC
Why SOAC will be a GREAT SPAC for Investors
"While a hint or two might be released on the current ReVolt Electric Motorcycle version, most design features will be kept under wraps pending the launch of production."
LOL
"Henryk Dabrowksi" Sounds like one of Russians that's puppetmastering the fuckwad in chief.
Well- Blackrock is buying SOMETHING today- didn't say who.
Got my 10% intraday- I'm out.
Total scam company!
Blackrock buying! Check their latest filings!
Will be .10 +++ with new contract pr and $100M in funding
MARK THIS POST!
New contract announcement soon:
"ALYI Expects To See Orders For ReVolt Electric Motorcycles Double Next Month
https://finance.yahoo.com/news/alyi-expects-see-orders-revolt-131500778.html
Read my last sentence
I'm buying down here, and this is why.
1. If they end up with the $100M financing (which seems a pretty sure thing), the stock will take off. Today's selloff was from people expecting news with more of a definitive statement on the financing.
2. The REvolt isn't on some drawing board like so many EV companies with $1B +++ valuations have. It's already taking orders @ https://www.revoltmotors.com/
And here is the bike in real life:
@ IanFromSI. Here's more info on TZAC that just came out today. (This is a SPAC that's acquiring Reviva Pharmaceuticals and will be listed on NASDAQ in Q4 - new ticker pending following completion of merger).
There are some comps on page 10
https://www.sec.gov/Archives/edgar/data/1742927/000110465920087685/tm2025979d1_ex99-1.htm
Only
lol- I answered the exact questions you had about cash balance and IP and with a $50m cash balance you value the company "at zero or less".
Thanks anyway!
OK- here's more background info then
Yes, they own all the IP. No debt and about $50m cash post merger.
I'll re-post this and hope Dew and you guys can give some insight
Please a look at this pipeline and give some comps you know of, or a ballpark range for the market cap? This is a private company at the moment.
Thanks
http://revivapharma.com/product_pipeline/
So the target is Reviva Pharmaceuticals
Tenzing Acquisition Corp SPAC merging with Reiva Pharmaceuticals
https://finance.yahoo.com/news/tenzing-acquisition-corp-reviva-pharmaceuticals-115400189.html
Looks like a solid pipeline of phase 2 and 3 psych drugs.
http://revivapharma.com/product_pipeline/
How to value it though? Post merger enterprise valuation $119m uses $10 price for the calculation. According to last Q SEC filings, there are only 2.7m shares outstanding.
Nobody here yet- but would appreciate any thoughts on the valuation here, or (better yet) some comps.
Cheers!
OT? Hope you guys can help me here...
Dew- if you need to delete this I understand. Would appreciate some feedback though if possible.
Can you guys take a look at this pipeline and give some comps you know of, or a ballpark range for the market cap? This is a private company at the moment.
Thanks
http://revivapharma.com/product_pipeline/
$NBRV apparently an unknown COVID-19 play
See pop-up on site
https://www.nabriva.com/
$MNLO Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
https://www.globenewswire.com/news-release/2020/06/02/2042185/0/en/Menlo-Therapeutics-Announces-Positive-Results-from-Phase-2-Trial-of-FCD105-for-the-Treatment-of-Moderate-to-Severe-Acne-Vulgaris.html
No- I'm talking about more recent institutional buying. Here's the link.
As of reporting date 5/20/20
Look at the Blackrock column- went from zero position to 2.9 million.
https://whalewisdom.com/stock/mnlo
KNOW WHAT YOU OWN
$CLVS- offering at $8.05, trading at $7.90
Anyone have any thoughts? Thinking of dipping in for a starter myself but can't seem to pull the trigger. Feel like it may get beat down more for another day or two.
Not sue what you find funny about it.
If you think institutional participation- especially a jump as big as this isn't bullish, then I'm not sure what to say.
My dca in MNLO is $1.42 and the PDUFA move is just starting.
This is a buy and hold for me- looking for $3.50-$4.00 by eoy and $5-$8 next year.
Anyway, good luck!
$SRNE- not only did I not buy it (I know this company pretty well), I bought $6 puts that have done very well.
$SRNE "The CEO overhyping in vitro data (not even pre-clinical animal data) is a red flag"
Agreed.
SRNE will be a good short (especially with their abysmal current ratio- an offering right about now seems likely).
That said, I believe it will run for 2-3 more days as most of the hyped COVID plays seem to.
$MNLO PDUFA 6/2 and institutions are buying
Blackrock initiated a position of just over 2M shares and there's a large net of new and increasing positions in the stock as of Friday 5/15/2020.
https://whalewisdom.com/stock/mnlo
$MNLO Institutional buying showing big increases in recent weeks
That weaker than expected Q1 is a gift to institutional investors who are buying the crap out of MNLO shares.
As of Friday's reporting date (5/15/2020) there's been big institutional buying...just scroll down to the table and look at the millions of new shares bought, new positions from Blackrock (over 2M shares, and many others)
https://whalewisdom.com/stock/mnlo
And when they're loaded up, the price will move again.
This is the time to BUY.
$RPEH down 40% as if it were about to declare BK.
Yet, 2020 guidance says:
"The Company expects its Operating Income to be in the range of $5 million to $9 million and Operating income, as adjusted* to be in the range of $13 million to $17 million. EBITDA, as adjusted (Historical CDMO) to be in the range of $33 million to $37 million and EBITDA, as adjusted (Standalone)* to be in the range of $26 million to $30 million."
Took a starter today. Might take a bit to recover but I can be patient.
$MNLO 6/2 PDUFA date and earnings Monday 5/11 before the bell.
earnings should be strong from new launch of Amzeeq (acne foam)- reportedly has a run rate of $20-25M.
More dd and links here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155398564
$MNLO is a cash cow being born with 6/2 PDUFA and recent China expansion.
Might want to take a look at Menlo Therapeutics (MNLO).
PDUFA 6/2 for FMX103 for moderate-to-severe papulopustular rosacea in adults. Phase 3 results: https://www.foamix.com/news-releases/news-release-details/foamix-announces-positive-topline-results-phase-3-program
250M market cap after 3/9/2020 merger with Foamix, with about $130M in cash.
Investor Presentation
http://ir.menlotherapeutics.com/static-files/9f09b650-c86a-4a01-a062-9a77d086f7c0
Cash Cow
Peak sales $250M plus
Launched Amzeeq,( https://www.amzeeq.com/ ) a topical mynocycline foam for acne this quarter with strong uptake and a run rate of $20-$25M according to Cowen in this article: https://blog.tipranks.com/3-biotech-stocks-under-4-with-big-upside-potential/
That $20-25M run rate does NOT include a rollout in China with a $10M up front payment announced a week ago: https://www.globenewswire.com/news-release/2020/04/23/2020865/0/en/Menlo-Therapeutics-and-Cutia-Therapeutics-Enter-into-Exclusive-License-Agreement-for-AMZEEQ-and-Approved-Topical-Minocycline-Products-in-Greater-China.html
(How many kids in China with zits?)
Expecting new territories for Amzeeq to be announced also per the press release.
Sales of Finacea restarting now, adding to sales that I don't think are included in the Cown note above.
There were supply chain issues and patent litigation involving Foamix and LEO Pharma which have been resolved in favor of MNLO/Foamix. At any rate, sales (as of April 2nd) were expected to resume "in the coming weeks" with royalty payments resuming.
Another drug, FMX105 (also for moderate to severe acne) in Phase 2 with top line results due out in the current quarter.
I think a market cap of $250M, with a 6/2 PDUFA, a $20-25M run rate estimated before expansion into China and resumption of Finacea sales, plus results from phase 2 of FMX105 due this Q, all combine to make MNLO an undervalued stock at $1.77/share.
I'm not too big on technicals with smaller, less active issues like MNLO (trades about 2-3M shares daily) but the stock did hold it's $1.70 support nicely yesterday during the market sell off and looks like if it can get thru some short term resistance at $1.87-$1.90 the next resistance isn't until $2.25 or so.
Would be happy to hear any thoughts anyone has on this one.
Would like to post some due diligence and links on a stock with 6/2 PDUFA, but not sure what the definition of "microcap" is here as definitions vary, and don't want to break any rules. It's 250M market cap.
$MNLO was waiting for a day like today to complete my position.
Really looking forward to Q1 report and of course 6/2 PDUFA. Just 4 weeks away now.
Have a great weekend guys.
$MNLO looking at $250 million-plus in peak sales per Cowen in this article out today. Don't believe this includes any potential sales in China from last week's pr.
“…our clinicians continue to highlight their even greater enthusiasm for FMX-103, given that rosacea – although a smaller overall market than acne – has very limited treatment options. Taking the likely lower penetration of Amzeeq into the massive acne market, combined with the likely high penetration of FMX-103 into the smaller rosacea market, we continue to believe that these opportunities could eventually each exceed $250 million-plus in peak sales, which is clearly not reflected in the current valuation.”
“the launch was progressing as well as – and if not better – than any recent launch in acne.” Total prescriptions hit the 2,150 mark for the week ending March 13, indicating a revenue run-rate of about $20-$25 million.
https://blog.tipranks.com/3-biotech-stocks-under-4-with-big-upside-potential/
$78,046 in sales
I have a Subway franchise makes almost 2X that in a quarter.
$TPIV: Q&A w Director of CMC operations at TapImmune
http://microcapresearch.com/tapimmune-cmc/